2022
Advances in antibody-drug conjugates for gynecologic malignancies
Tymon-Rosario J, Gorman M, Richardson D, Washington C, Santin A. Advances in antibody-drug conjugates for gynecologic malignancies. Current Opinion In Obstetrics & Gynecology 2022, 35: 6-14. PMID: 36484278, DOI: 10.1097/gco.0000000000000838.Peer-Reviewed Original ResearchConceptsAntibody-drug conjugatesOvarian cancer patientsGynecologic malignanciesCancer patientsPlatinum-resistant ovarian cancer patientsUse of ADCsOngoing phase 3 trialsRecurrent ovarian cancer patientsNovel antibody-drug conjugateReceptor-targeting antibodiesPhase 3 trialProgression-free survivalFirst U.S. FoodOngoing clinical trialsHER2/neuPersonalized cancer careTisotumab vedotinPrimary endpointCervical cancerGynecologic cancerCancer careClinical trialsMultiple tumorsCurrent evidenceDrug Administration
2021
Comparison of radiomic feature aggregation methods for patients with multiple tumors
Chang E, Joel MZ, Chang HY, Du J, Khanna O, Omuro A, Chiang V, Aneja S. Comparison of radiomic feature aggregation methods for patients with multiple tumors. Scientific Reports 2021, 11: 9758. PMID: 33963236, PMCID: PMC8105371, DOI: 10.1038/s41598-021-89114-6.Peer-Reviewed Original ResearchConceptsCox proportional hazards modelCox proportional hazardsProportional hazards modelBrain metastasesRadiomic featuresHazards modelProportional hazardsStandard Cox proportional hazards modelMultifocal brain metastasesMultiple brain metastasesNumber of patientsPatient-level outcomesHigher concordance indexRadiomic feature analysisRandom survival forest modelSurvival modelsDifferent tumor volumesMultifocal tumorsCancer outcomesMultiple tumorsMetastatic cancerConcordance indexTumor volumePatientsTumor types
2020
Novel antibody-drug conjugates: current and future roles in gynecologic oncology.
Tymon-Rosario J, Zeybek B, Santin AD. Novel antibody-drug conjugates: current and future roles in gynecologic oncology. Current Opinion In Obstetrics & Gynecology 2020, 33: 26-33. PMID: 32618744, PMCID: PMC8253558, DOI: 10.1097/gco.0000000000000642.Peer-Reviewed Original ResearchConceptsAntibody-drug conjugatesAntigen-negative cellsNovel antibody-drug conjugateAggressive gynecologic malignancyReceptor-targeting antibodiesTrop-2 overexpressionOngoing clinical trialsHER2/neuPersonalized cancer careNormal surrounding tissueAntigen-positive target cellsGynecologic malignanciesGynecologic tumorsCervical cancerSacituzumab govitecanCancer careGynecologic oncologyPreclinical dataTrastuzumab emtansineADC therapyClinical trialsMultiple tumorsCurrent standard practiceNoncleavable linkerCytotoxic moleculesLiver transplantation in the treatment of unresectable hepatic metastasis from neuroendocrine tumors
Kim J, Zimmerman M, Hong J. Liver transplantation in the treatment of unresectable hepatic metastasis from neuroendocrine tumors. Journal Of Gastrointestinal Oncology 2020, 11: 601-608. PMID: 32655939, PMCID: PMC7340808, DOI: 10.21037/jgo.2019.11.03.Peer-Reviewed Original ResearchPost-OLT outcomesOrthotopic liver transplantationNeuroendocrine tumorsLiver metastasesLiver transplantationTreatment of unresectable hepatic metastasesPatients of neuroendocrine tumorsRecurrence-free patient survivalUnresectable hepatic metastasesPrediction of survival outcomesPrimary neuroendocrine tumorsUnresectable liver metastasesReview patient selection criteriaLiver neuroendocrine tumorsRate of recurrencePatient selection criteriaHepatic metastasesPrognostic factorsRare neoplasmsPost-OLTDefinitive treatmentMetastatic spreadSurvival outcomesPatient survivalMultiple tumors
2018
Recent advances in field cancerization and management of multiple cutaneous squamous cell carcinomas
Christensen SR. Recent advances in field cancerization and management of multiple cutaneous squamous cell carcinomas. F1000Research 2018, 7: f1000 faculty rev-690. PMID: 29904586, PMCID: PMC5989149, DOI: 10.12688/f1000research.12837.1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSquamous cell carcinomaMultiple squamous cell carcinomasCutaneous squamous cell carcinomaField cancerizationPrecursor lesionsCell carcinomaMultiple cutaneous squamous cell carcinomasIncident squamous cell carcinomaSubsequent squamous cell carcinomaField-directed therapySevere actinic damageTopical ingenol mebutateMultiple primary cancersManagement of patientsSubsequent cancer developmentSystemic acitretinTopical imiquimodPrimary cancerCommon cancerMultiple tumorsIngenol mebutateSCC developmentActinic damageField therapyPatients
2015
von Hippel–Lindau Disease
Ramirez A, Smith P. von Hippel–Lindau Disease. 2015, 347-359. DOI: 10.1007/978-3-319-13662-2_56.Peer-Reviewed Original ResearchClinical care centersAutosomal dominant heritable disorderCare centerExtra-adrenal paragangliomasPancreatic neuroendocrine tumorsEndolymphatic sac tumorsRenal cell carcinomaVHL-associated lesionsBroad ligament cystadenomasRetinal hemangioblastomaNeuroendocrine tumorsSac tumorCell carcinomaImproved life expectancyEndocrine surgeonsSurgical interventionMultiple tumorsPancreatic cystsAbstractvon Hippel–LindauScreening guidelinesNeoplasia developmentClinical evaluationScheduled imagingTumorCausative mutations
2014
Multiple Sporadic Colorectal Cancers Display a Unique Methylation Phenotype
Gonzalo V, Lozano JJ, Alonso-Espinaco V, Moreira L, Muñoz J, Pellisé M, Castellví-Bel S, Bessa X, Andreu M, Xicola RM, Llor X, Ruiz-Ponte C, Carracedo A, Jover R, Castells A, Balaguer F. Multiple Sporadic Colorectal Cancers Display a Unique Methylation Phenotype. PLOS ONE 2014, 9: e91033. PMID: 24643221, PMCID: PMC3958343, DOI: 10.1371/journal.pone.0091033.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overColorectal NeoplasmsCpG IslandsDNA MethylationEpigenesis, GeneticFemaleGene Expression Regulation, NeoplasticGenome-Wide Association StudyGenotypeHumansMaleMiddle AgedNeoplasms, Multiple PrimaryPhenotypeProto-Oncogene ProteinsProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)ras ProteinsConceptsMultiple colorectal cancersColorectal cancerSporadic colorectal cancerMultiple tumorsCpG island methylator phenotypeSolitary tumorTumor multiplicityMismatch repair deficiency statusSynchronous colorectal cancerMethylation phenotypeCIMP-high tumorsDNA methylation profilingDNA hypermethylationBRAF mutationsDeficiency statusSignificant DNA hypermethylationTumorsTumor samplesMethylation profilingMethyLight assayTumor pairsMethylator phenotypeCpG sitesFunctional annotation clusteringPatients
2011
Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1
Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry C, Xie TX, Zhang J, Wang J, Zhang N, El-Naggar AK, Jasser SA, Weinstein JN, Treviño L, Drummond JA, Muzny DM, Wu Y, Wood LD, Hruban RH, Westra WH, Koch WM, Califano JA, Gibbs RA, Sidransky D, Vogelstein B, Velculescu VE, Papadopoulos N, Wheeler DA, Kinzler KW, Myers JN. Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1. Science 2011, 333: 1154-1157. PMID: 21798897, PMCID: PMC3162986, DOI: 10.1126/science.1206923.Peer-Reviewed Original ResearchMeSH KeywordsCarcinomaCarcinoma, Squamous CellCell Cycle ProteinsCodon, NonsenseExonsF-Box ProteinsF-Box-WD Repeat-Containing Protein 7Gene DosageGenes, p53Genes, Tumor SuppressorHead and Neck NeoplasmsHumansINDEL MutationMutationMutation, MissenseNeoplasms, Squamous CellOligonucleotide Array Sequence AnalysisOncogenesPapillomaviridaePapillomavirus InfectionsReceptor, Notch1Sequence Analysis, DNASmokingSquamous Cell Carcinoma of Head and NeckUbiquitin-Protein LigasesConceptsNeck squamous cell carcinomaSquamous cell carcinomaCell carcinomaHuman papillomavirusHPV-positive tumorsWhole-exome sequencingMore mutationsPrimary tumorCommon cancerMultiple tumorsTobacco useTumor typesTumorsTumor suppressor geneExome sequencingGene copy number analysisNotch1Copy number analysisPatientsCarcinomaInactivating mutationCancerSuppressor geneMutationsGenetic origin
2001
Intrahepatic Cholangiocarcinoma: resectability, recurrence pattern, and outcomes1 1No competing interests declared.
Weber S, Jarnagin W, Klimstra D, DeMatteo R, Fong Y, Blumgart L. Intrahepatic Cholangiocarcinoma: resectability, recurrence pattern, and outcomes1 1No competing interests declared. Journal Of The American College Of Surgeons 2001, 193: 384-391. PMID: 11584966, DOI: 10.1016/s1072-7515(01)01016-x.Peer-Reviewed Original ResearchConceptsIntrahepatic cholangiocarcinomaVascular invasionHepatic tumorsMultiple tumorsFactors PredictiveActuarial 3-year survivalRare primary hepatic tumorDisease-free survival ratesFactors predictive of recurrencePredictive of poor survivalHistologically positive marginsOverall resection rateSite of recurrenceDisease-free survivalAdjuvant therapy strategiesPredictive of recurrencePrimary hepatic tumorsRecurrence patternsBile duct originPositive marginsComplete resectionCurative resectionMedian survivalTumor characteristicsProspective database
1973
Neoplasms of transitional cell origin in first twenty years of life
McGuire E, Weiss R, Baskin A. Neoplasms of transitional cell origin in first twenty years of life. Urology 1973, 1: 57-59. PMID: 4792287, DOI: 10.1016/0090-4295(73)90114-3.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply